German doctors' president slams health reforms:
This article was originally published in Clinica
Executive Summary
German federal health minister Ulla Schmidt has reacted furiously to claims by the president of the German doctors chamber (BAK), Jorg Dietrich Hoppe, that her health reforms have seriously reduced the number of procedures on offer. "There will soon be regions where people should not go [for treatment], because none will be available," he told delegates to the German doctors' congress in Bremen this week. Professor Hoppe added that the diagnosis related groups (DRG) system for hospital reimbursement was encouraging specialisation, which meant that many hospitals could not longer offer a broad spectrum of procedures, and added that the reforms were promoting "medical care for the rich". Ms Schmidt has denied the allegations and demanded an apology.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.